{"id":201447,"date":"2023-08-08T00:30:12","date_gmt":"2023-08-08T07:30:12","guid":{"rendered":"https:\/\/www.shockya.com\/news\/?p=201447"},"modified":"2023-08-07T09:06:40","modified_gmt":"2023-08-07T16:06:40","slug":"introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression","status":"publish","type":"post","link":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/","title":{"rendered":"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression"},"content":{"rendered":"<p><a href=\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg\"><img decoding=\"async\" src=\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg\" alt=\"\" width=\"600\" class=\"alignnone size-full wp-image-201448\" srcset=\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg 500w, https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression-200x300.jpeg 200w\" sizes=\"(max-width: 500px) 100vw, 500px\" \/><\/a><\/p>\n<p>In a groundbreaking stride forward for women&#8217;s mental health, the U.S. Food and Drug Administration has granted its seal of approval to a momentous innovation &#8211; the very first oral medication meticulously designed to combat the harrowing grip of <a href=\"https:\/\/www.cnn.com\/2023\/08\/04\/health\/fda-approves-first-postpartum-depression-pill-in-the-us\/index.html\">severe postpartum depression<\/a>. This monumental decision, announced recently, ushers in newfound hope and potential solace for countless mothers grappling with the overwhelming and often life-threatening emotional turmoil that accompanies this debilitating condition.<\/p>\n<blockquote class=\"twitter-tweet\">\n<p lang=\"en\" dir=\"ltr\">Today, we approved the first oral medication indicated to treat postpartum depression in adults. <a href=\"https:\/\/t.co\/z8SD0o2GUV\">https:\/\/t.co\/z8SD0o2GUV<\/a> <a href=\"https:\/\/t.co\/EJzoE73Q79\">pic.twitter.com\/EJzoE73Q79<\/a><\/p>\n<p>&mdash; U.S. FDA (@US_FDA) <a href=\"https:\/\/twitter.com\/US_FDA\/status\/1687598234015850496?ref_src=twsrc%5Etfw\">August 4, 2023<\/a><\/p><\/blockquote>\n<p> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script> <\/p>\n<p>&#8220;Unlocking access to an oral remedy stands as a pivotal and advantageous alternative for the multitude of women navigating through the throes of profound, and occasionally perilous, sentiments,&#8221; conveyed Dr. Tiffany Farchione, the astute and dedicated director of psychiatric medications at the esteemed FDA, in a compelling declaration on a vibrant Friday morning.<\/p>\n<p>Marking an incredible stride in medical science, the newly sanctioned drug christened as Zurzuvae, boasts a simple regimen &#8211; a solitary daily dose over the course of a fortnight. Reserved explicitly for cases of severe postpartum depression, this therapeutic marvel, conceived and brought to fruition by the venerable Sage Therapeutics headquartered in Massachusetts, has already garnered widespread attention for its transformative potential.<\/p>\n<p>The endorsement arrives on the heels of two groundbreaking studies that meticulously scrutinized the efficacy of Zurzuvae, painting an encouraging portrait of its impact. A noteworthy testimonial arises from Sahar McMahon, a remarkable 39-year-old woman who elected to partake in the study, driven by an innate desire to mend her bond with her children. Sahar&#8217;s poignant journey of healing serves as a poignant reminder of the profound and far-reaching impact that this pioneering medication promises to bestow upon women ensnared by the clutches of severe postpartum depression.<\/p>\n<p>The impetus behind this revolutionary breakthrough stemmed from an unwavering commitment to alleviate the anguish that mothers often endure silently. As Sage Therapeutics set forth on a remarkable mission to fashion a beacon of hope, their dedication to unraveling the intricate threads of this emotional labyrinth led to the creation of Zurzuvae, a beacon of optimism amid the darkest of times.<\/p>\n<p>In a world where the nuanced nuances of mental health are gradually being illuminated, this monumental stride is poised to set a new precedent. By offering a tangible remedy to an affliction that has long remained shrouded in shadows, Zurzuvae&#8217;s ascendancy paves the way for countless women to rewrite their narratives, rekindling the flames of connection, joy, and fulfillment that motherhood so profoundly entails.<\/p>\n<p>So, as the pages of medical history turn to welcome the epochal <a href=\"https:\/\/www.nbcnews.com\/health\/health-news\/first-pill-postpartum-depression-fda-approval-rcna97731\">arrival of Zurzuvae<\/a>, let us remain steadfast in our commitment to empathy, support, and understanding. Together, we can amplify the voices of those who have long suffered in silence, ensuring that the dawn of a new era in women&#8217;s mental health is characterized by healing, resilience, and unshakable hope.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a groundbreaking stride forward for women&#8217;s mental health, the U.S. Food and Drug Administration has granted its seal of approval to a momentous innovation &#8211; the very first oral medication meticulously designed to combat the harrowing grip of severe postpartum depression. This monumental decision, announced recently, ushers in newfound hope and potential solace for [&hellip;]<\/p>\n","protected":false},"author":74,"featured_media":201448,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"jetpack_post_was_ever_published":false,"apple_news_api_created_at":"2023-08-08T07:30:26Z","apple_news_api_id":"442aa17f-f5d4-4c97-b027-45227c3d3839","apple_news_api_modified_at":"2023-08-08T07:30:27Z","apple_news_api_revision":"AAAAAAAAAAD\/\/\/\/\/\/\/\/\/\/w==","apple_news_api_share_url":"https:\/\/apple.news\/ARCqhf_XUTJewJ0UifD04OQ","apple_news_cover_media_provider":"image","apple_news_coverimage":0,"apple_news_coverimage_caption":"","apple_news_cover_video_id":0,"apple_news_cover_video_url":"","apple_news_cover_embedwebvideo_url":"","apple_news_is_hidden":"","apple_news_is_paid":"","apple_news_is_preview":"","apple_news_is_sponsored":"","apple_news_maturity_rating":"","apple_news_metadata":"\"\"","apple_news_pullquote":"","apple_news_pullquote_position":"middle","apple_news_slug":"","apple_news_sections":["https:\/\/news-api.apple.com\/sections\/a256d957-d5f8-3bec-b93f-7f862cadbf92"],"apple_news_suppress_video_url":false,"apple_news_use_image_component":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[44642,1],"tags":[47837,47102,9926,47833,47835,47836,47834],"class_list":["post-201447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-news-release","tag-emotional-well-being","tag-fda-approval","tag-motherhood","tag-postpartum-depression","tag-sage-therapeutics","tag-womens-mental-health","tag-zurzuvae"],"apple_news_notices":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression<\/title>\n<meta name=\"description\" content=\"In a groundbreaking stride forward for women&#039;s mental health, the U.S. Food and Drug Administration has granted its seal of approval to a momentous Explore the transformative impact of Zurzuvae, the FDA-approved pill offering newfound hope to mothers battling severe postpartum depression. Unveil a beacon of optimism as Sage Therapeutics pioneers a breakthrough in women&#039;s mental health.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression\" \/>\n<meta property=\"og:description\" content=\"In a groundbreaking stride forward for women&#039;s mental health, the U.S. Food and Drug Administration has granted its seal of approval to a momentous Explore the transformative impact of Zurzuvae, the FDA-approved pill offering newfound hope to mothers battling severe postpartum depression. Unveil a beacon of optimism as Sage Therapeutics pioneers a breakthrough in women&#039;s mental health.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/shockyafans\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-08T07:30:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"750\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alki David\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@shockya\" \/>\n<meta name=\"twitter:site\" content=\"@shockya\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alki David\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/\"},\"author\":{\"name\":\"Alki David\",\"@id\":\"https:\/\/www.shockya.com\/news\/#\/schema\/person\/1cd98c110056295f03f43aaa25aaebb4\"},\"headline\":\"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression\",\"datePublished\":\"2023-08-08T07:30:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/\"},\"wordCount\":508,\"publisher\":{\"@id\":\"https:\/\/www.shockya.com\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg\",\"keywords\":[\"EMOTIONAL WELL-BEING\",\"FDA approval\",\"MOTHERHOOD\",\"POSTPARTUM DEPRESSION\",\"SAGE THERAPEUTICS\",\"WOMEN'S MENTAL HEALTH\",\"ZURZUVAE\"],\"articleSection\":[\"HEALTH AND WELLNESS\",\"NEWS\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/\",\"url\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/\",\"name\":\"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression\",\"isPartOf\":{\"@id\":\"https:\/\/www.shockya.com\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg\",\"datePublished\":\"2023-08-08T07:30:12+00:00\",\"description\":\"In a groundbreaking stride forward for women's mental health, the U.S. Food and Drug Administration has granted its seal of approval to a momentous Explore the transformative impact of Zurzuvae, the FDA-approved pill offering newfound hope to mothers battling severe postpartum depression. Unveil a beacon of optimism as Sage Therapeutics pioneers a breakthrough in women's mental health.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#primaryimage\",\"url\":\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg\",\"contentUrl\":\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg\",\"width\":500,\"height\":750},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.shockya.com\/news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.shockya.com\/news\/#website\",\"url\":\"https:\/\/www.shockya.com\/news\/\",\"name\":\"\",\"description\":\"REAL TALK\",\"publisher\":{\"@id\":\"https:\/\/www.shockya.com\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.shockya.com\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.shockya.com\/news\/#organization\",\"name\":\"Anakando Media Group\",\"url\":\"https:\/\/www.shockya.com\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.shockya.com\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/anakando.jpg\",\"contentUrl\":\"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/anakando.jpg\",\"width\":237,\"height\":213,\"caption\":\"Anakando Media Group\"},\"image\":{\"@id\":\"https:\/\/www.shockya.com\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/shockyafans\/\",\"https:\/\/x.com\/shockya\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.shockya.com\/news\/#\/schema\/person\/1cd98c110056295f03f43aaa25aaebb4\",\"name\":\"Alki David\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.shockya.com\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2bdc5aebe379a74217f90fdacb985c45b22259821e4d4bb8bfc0f12832443d77?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2bdc5aebe379a74217f90fdacb985c45b22259821e4d4bb8bfc0f12832443d77?s=96&d=mm&r=g\",\"caption\":\"Alki David\"},\"description\":\"Alki David \u2014 Publisher, Media Architect, SIN Network Creator - live, direct-to-public communication, media infrastructure, accountability journalism, and independent distribution. Born in Lagos, Nigeria; educated in the United Kingdom and Switzerland; attended the Royal College of Art. Early internet broadcaster \u2014 participated in real-time public coverage during the 1997 Mars landing era using experimental online transmission from Beverly Hills. Founder of FilmOn, one of the earliest global internet television networks offering live and on-demand broadcasting outside legacy gatekeepers. Publisher of SHOCKYA \u2014 reporting since 2010 on systemic corruption inside the entertainment business and its expansion into law, finance, and regulation. Creator of the SIN Network (ShockYA Integrated Network), a federated media and civic-information infrastructure spanning investigative journalism, live TV, documentary, and court-record reporting. Lived and worked for over 40 years inside global media hubs including Malibu, Beverly Hills, London, Hong Kong and Gstaad. Early encounter with Julian Assange during the first Hologram USA operations proved a formative turning point \u2014 exposing the realities of lawfare, information suppression, and concentrated media power. Principal complainant and driving force behind what court filings describe as the largest consolidated media\u2013legal accountability action on record, now before the Eastern Caribbean Supreme Court. Relocated to Antigua &amp; Barbuda and entered sustained legal, civic, and informational confrontation over media power, safeguarding, and accountability at Commonwealth scale.\",\"sameAs\":[\"https:\/\/www.instagram.com\/alkidavid\"],\"url\":\"https:\/\/www.shockya.com\/news\/author\/grady\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression","description":"In a groundbreaking stride forward for women's mental health, the U.S. Food and Drug Administration has granted its seal of approval to a momentous Explore the transformative impact of Zurzuvae, the FDA-approved pill offering newfound hope to mothers battling severe postpartum depression. Unveil a beacon of optimism as Sage Therapeutics pioneers a breakthrough in women's mental health.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/","og_locale":"en_US","og_type":"article","og_title":"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression","og_description":"In a groundbreaking stride forward for women's mental health, the U.S. Food and Drug Administration has granted its seal of approval to a momentous Explore the transformative impact of Zurzuvae, the FDA-approved pill offering newfound hope to mothers battling severe postpartum depression. Unveil a beacon of optimism as Sage Therapeutics pioneers a breakthrough in women's mental health.","og_url":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/","article_publisher":"https:\/\/www.facebook.com\/shockyafans\/","article_published_time":"2023-08-08T07:30:12+00:00","og_image":[{"width":500,"height":750,"url":"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg","type":"image\/jpeg"}],"author":"Alki David","twitter_card":"summary_large_image","twitter_creator":"@shockya","twitter_site":"@shockya","twitter_misc":{"Written by":"Alki David","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#article","isPartOf":{"@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/"},"author":{"name":"Alki David","@id":"https:\/\/www.shockya.com\/news\/#\/schema\/person\/1cd98c110056295f03f43aaa25aaebb4"},"headline":"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression","datePublished":"2023-08-08T07:30:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/"},"wordCount":508,"publisher":{"@id":"https:\/\/www.shockya.com\/news\/#organization"},"image":{"@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#primaryimage"},"thumbnailUrl":"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg","keywords":["EMOTIONAL WELL-BEING","FDA approval","MOTHERHOOD","POSTPARTUM DEPRESSION","SAGE THERAPEUTICS","WOMEN'S MENTAL HEALTH","ZURZUVAE"],"articleSection":["HEALTH AND WELLNESS","NEWS"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/","url":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/","name":"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression","isPartOf":{"@id":"https:\/\/www.shockya.com\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#primaryimage"},"image":{"@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#primaryimage"},"thumbnailUrl":"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg","datePublished":"2023-08-08T07:30:12+00:00","description":"In a groundbreaking stride forward for women's mental health, the U.S. Food and Drug Administration has granted its seal of approval to a momentous Explore the transformative impact of Zurzuvae, the FDA-approved pill offering newfound hope to mothers battling severe postpartum depression. Unveil a beacon of optimism as Sage Therapeutics pioneers a breakthrough in women's mental health.","breadcrumb":{"@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#primaryimage","url":"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg","contentUrl":"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg","width":500,"height":750},{"@type":"BreadcrumbList","@id":"https:\/\/www.shockya.com\/news\/2023\/08\/08\/introducing-a-breakthrough-fda-greenlights-first-ever-pill-targeting-severe-postpartum-depression\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.shockya.com\/news\/"},{"@type":"ListItem","position":2,"name":"Introducing a Breakthrough: FDA Greenlights First-Ever Pill Targeting Severe Postpartum Depression"}]},{"@type":"WebSite","@id":"https:\/\/www.shockya.com\/news\/#website","url":"https:\/\/www.shockya.com\/news\/","name":"","description":"REAL TALK","publisher":{"@id":"https:\/\/www.shockya.com\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.shockya.com\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.shockya.com\/news\/#organization","name":"Anakando Media Group","url":"https:\/\/www.shockya.com\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.shockya.com\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/anakando.jpg","contentUrl":"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/anakando.jpg","width":237,"height":213,"caption":"Anakando Media Group"},"image":{"@id":"https:\/\/www.shockya.com\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/shockyafans\/","https:\/\/x.com\/shockya"]},{"@type":"Person","@id":"https:\/\/www.shockya.com\/news\/#\/schema\/person\/1cd98c110056295f03f43aaa25aaebb4","name":"Alki David","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.shockya.com\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2bdc5aebe379a74217f90fdacb985c45b22259821e4d4bb8bfc0f12832443d77?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2bdc5aebe379a74217f90fdacb985c45b22259821e4d4bb8bfc0f12832443d77?s=96&d=mm&r=g","caption":"Alki David"},"description":"Alki David \u2014 Publisher, Media Architect, SIN Network Creator - live, direct-to-public communication, media infrastructure, accountability journalism, and independent distribution. Born in Lagos, Nigeria; educated in the United Kingdom and Switzerland; attended the Royal College of Art. Early internet broadcaster \u2014 participated in real-time public coverage during the 1997 Mars landing era using experimental online transmission from Beverly Hills. Founder of FilmOn, one of the earliest global internet television networks offering live and on-demand broadcasting outside legacy gatekeepers. Publisher of SHOCKYA \u2014 reporting since 2010 on systemic corruption inside the entertainment business and its expansion into law, finance, and regulation. Creator of the SIN Network (ShockYA Integrated Network), a federated media and civic-information infrastructure spanning investigative journalism, live TV, documentary, and court-record reporting. Lived and worked for over 40 years inside global media hubs including Malibu, Beverly Hills, London, Hong Kong and Gstaad. Early encounter with Julian Assange during the first Hologram USA operations proved a formative turning point \u2014 exposing the realities of lawfare, information suppression, and concentrated media power. Principal complainant and driving force behind what court filings describe as the largest consolidated media\u2013legal accountability action on record, now before the Eastern Caribbean Supreme Court. Relocated to Antigua &amp; Barbuda and entered sustained legal, civic, and informational confrontation over media power, safeguarding, and accountability at Commonwealth scale.","sameAs":["https:\/\/www.instagram.com\/alkidavid"],"url":"https:\/\/www.shockya.com\/news\/author\/grady\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/www.shockya.com\/news\/wp-content\/uploads\/Postpartum-Depression.jpeg","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pnMiA-Qp9","distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"","distributor_original_site_url":"https:\/\/www.shockya.com\/news","push-errors":false,"_links":{"self":[{"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/posts\/201447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/users\/74"}],"replies":[{"embeddable":true,"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/comments?post=201447"}],"version-history":[{"count":0,"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/posts\/201447\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/media\/201448"}],"wp:attachment":[{"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/media?parent=201447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/categories?post=201447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.shockya.com\/news\/wp-json\/wp\/v2\/tags?post=201447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}